OCRA News

Getting Creative for the Cause | Heroes Highlights

Ready, set, action! This group of OCRA Heroes has taken those words to heart by using their creative talents to make a concrete difference for the ovarian cancer community…

Read on

Metastatic Ovarian Cancer

Metastatic ovarian cancer is cancer that has spread from the ovaries, or the fallopian tubes, to parts of the body outside the site of origin. Ovarian cancer that has metastasized is classified as Stage IV…

Read on

High Grade Serous Carcinoma

High grade serous carcinoma is the most common type of ovarian cancer, accounting for approximately 75% of epithelial ovarian cancers…

Read on

Inspired Advice: What Would You Tell Someone Who Has a Recurrence?

Those who have faced an ovarian or gynecologic cancer diagnosis have so much to offer to others going through a similar experience – be it support, tips or friendship…

Read on

The Overview: July 2021

Sultry summer days can make anyone feel lazy and daydream of faraway places. But at OCRA, we’re working as hard as ever to fulfill our dream of a day when no one need fear an ovarian cancer diagnosis…

Read on

OCRA’s Statement on the Introduction of HR 4412 to Reauthorize Johanna’s Law

Your Representative needs to hear from YOU…

Read on

Does Ovarian Cancer Stop Periods?

No, ovarian cancer does not stop your period in and of itself. It is still possible to menstruate with the presence of the disease in your body…

Read on

Oral Contraceptives Associated with Lower Ovarian Cancer Risk in BRCA Mutation Carriers

A study published in the American Journal of Obstetrics & Gynecology provides new insight into previously established research that oral contraceptive use is connected to lower ovarian cancer risk in the general population, by more closely…

Read on

OCRA-Funded Study Identifies Antibiotic Found to Kill Tumor Cells Containing BRCA Mutations

A long-running study from Dana-Farber Cancer Institute, published in Nature Cancer and co-funded by OCRA, has discovered that the antibiotic novobiocin is capable of targeting and killing tumor cells in laboratory cell lines and tumor models with…

Read on

Racing to Cure Ovarian Cancer | Heroes Highlights

As our community continues to come together to make strides against ovarian cancer, we want to give a shout-out to our many OCRA Heroes who push themselves physically, creatively or in myriad other ways to raise money for research…

Read on

OCRA’s Woman to Woman Program Touted in Qualitative Study

Researchers from the University of Kansas School of Medicine conducted a study to capture the value and experience of giving and receiving peer support in the face of a gynecologic cancer diagnosis by interviewing Woman to Woman mentors…

Read on

What is Lynch Syndrome?

Inherited gene mutations, such as BRCA 1 and BRCA 2, can increase the risk of developing ovarian cancer. Some of these mutations, which affect MLHL, MSH2, MSH6, PMS2 and EPCAM genes, can cause Lynch Syndrome…

Read on